Seraseq™ ctDNA: A Breakthrough QC Technology
The Most Patient-Like ctDNA Reference Material
The advances in liquid biopsy technology have outpaced improvements of accompanying ctDNA QC materials and methods. The lack of a sustainable source of patient-like reference materials with rare, pathogenic variants has frustrated both assay developers and clinical laboratory directors. SeraCare have developed a new technology to overcome the inherent challenges of using remnant patient samples and ultrasonicated cancer cell lines for ctDNA assay development and validation.
Read the white paper to see data and in-depth analysis on:
- The three heretofore unsolved challenges of working with ctDNA
- What makes a material patient-like, and why this matters
- Appropriate size distribution and library yield